Evidence map›Paper›PMID 38961226›Full record

ArticleNature medicine2024

Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Glenn M Chertow, Anna Marie Chang, G Michael Felker, Mark Heise, Elena Velkoska, Bengt Fellström, David M Charytan, Regina Clementi, C Michael Gibson, Shaun G Goodman and 13 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Glenn M ChertowStanford University, Palo Alto, CA, USA. gchertow@stanford.edu.ORCID http://orcid.org/0000-0002-7599-0534
Anna Marie ChangCSL Behring, King of Prussia, PA, USA.
G Michael FelkerDuke University, Durham, NC, USA.
Mark HeiseCSL Behring, King of Prussia, PA, USA.ORCID http://orcid.org/0009-0002-6064-0280
Elena VelkoskaCSL Limited, Melbourne, Victoria, Australia.
Bengt FellströmUppsala University, Uppsala, Sweden.
David M CharytanNew York University, New York City, NY, USA.
Regina ClementiCSL Behring, King of Prussia, PA, USA.
C Michael GibsonHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4857-9125
Shaun G GoodmanUniversity of Toronto and University of Alberta, Edmonton, Alberta, Canada.
Meg JardineUniversity of Sydney, Sydney, New South Wales, Australia.
Adeera LevinUniversity of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0003-2438-8401
Yuliya LokhnyginaDuke University, Durham, NC, USA.
Jenny MearsCSL Behring, King of Prussia, PA, USA.
Roxana MehranMt Sinai Hospital, New York City, NY, USA.
Peter StenvinkelKarolinska Institute, Solna, Sweden.ORCID http://orcid.org/0000-0002-8785-4820
Angela Yee-Moon WangHong Kong University, Hong Kong, China.ORCID http://orcid.org/0000-0003-2508-7117
David C WheelerUniversity College London, London, UK.
Carmine ZoccaliOspedali Riuniti Reggio Calabria, Reggio di Calabria, Italy.ORCID http://orcid.org/0000-0002-6616-1996
Paul M RidkerHarvard Medical School, Boston, MA, USA.
Kenneth W MahaffeyStanford University, Palo Alto, CA, USA.
Pierluigi TricociCSL Behring, King of Prussia, PA, USA.
Myles WolfDuke University, Durham, NC, USA.ORCID http://orcid.org/0000-0002-1127-1442

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38961226
PMCPMC11333268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.